Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, January 15, 2024

Flow diverters with surface modification in patients with intracranial aneurysms: a systematic review and meta-analysis

 Ask your doctor if this intervention guarantees no strokes as a result.

Flow diverters with surface modification in patients with intracranial aneurysms: a systematic review and meta-analysis

, , , , ,
https://doi.org/10.1016/j.wneu.2023.12.132Get rights and content

Abstract

Background

Flow diverters with surface modification (FDSM) are increasingly used in the treatment of intracranial aneurysms. We aimed to evaluate the effectiveness and safety across different devices and antiplatelet therapies using a systematic review and meta-analysis.

Methods

A systematic review was performed to identify original studies of ≥10 patients with intracranial aneurysms treated with FDSM from database inception through August 2023. Primary effectiveness outcome was the rate of complete aneurysm occlusion at follow-up ≥6 months. Safety outcomes included ischemic stroke, hemorrhage and in-stent thrombosis, and were stratified by FDSM devices and antiplatelet therapies. Certainty of evidence was evaluated following the GRADE approach.

Results

Twenty-seven studies were included, yielding 2161 patients with 2373 aneurysms. 70.5% of the aneurysms were located on the internal carotid artery (ICA). 10.3% were acutely ruptured. The complete aneurysm occlusion rate was 72.3% at follow-up ≥6 months. Sensitivity analysis in the ICA aneurysm cohort yielded comparable occlusion rates between PED-Shield (80.4%) and Phenox-HPC (77.5%, P=0.54), but a lower 66.2% rate for FRED-X (P=0.02). The rate of in-stent thrombosis and stenosis tended to be higher in Phenox-HPC (3.4%) and FRED-X (4.3%) versus PED-Shield (0.8%, P=0.05).

Conclusions

FDSM were safe with satisfactory effectiveness for intracranial aneurysms. More specific investigations are warranted to explore their performance in aneurysms beyond the ICA and optimal antiplatelet therapy.

Posted by at
Labels: , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)